

# Paul L Prather

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4276031/publications.pdf>

Version: 2024-02-01

41  
papers

1,221  
citations

516215

16  
h-index

360668

35  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1252  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to $\Delta^9$ -THC: Mechanism underlying greater toxicity?. <i>Life Sciences</i> , 2014, 97, 45-54.	2.0	236
2	Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity. <i>PLoS ONE</i> , 2011, 6, e21917.	1.1	192
3	Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. <i>Biochemical Pharmacology</i> , 2012, 83, 952-961.	2.0	143
4	The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. <i>Drug Metabolism Reviews</i> , 2014, 46, 72-85.	1.5	102
5	Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. <i>Toxicology and Applied Pharmacology</i> , 2013, 269, 100-108.	1.3	78
6	Synthetic Pot: Not Your Grandfather's Marijuana. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 257-276.	4.0	78
7	The Endocannabinoid Noladin Ether Acts as a Full Agonist at Human CB2 Cannabinoid Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 868-875.	1.3	74
8	Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development. <i>Pharmacological Research</i> , 2017, 125, 161-177.	3.1	32
9	Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 597-602.	1.0	24
10	CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 339-343.	1.0	21
11	Palmitoylethanolamide Regulates Development of Intestinal Radiation Injury in a Mast Cell-Dependent Manner. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2693-2703.	1.1	21
12	Antinociceptive effects of the 6- O -sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors. <i>Pharmacological Research</i> , 2016, 113, 335-347.	3.1	21
13	Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity. <i>Frontiers in Pharmacology</i> , 2016, 7, 503.	1.6	20
14	Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to $\Delta^9$ -THC. <i>Frontiers in Pharmacology</i> , 2018, 9, 1084.	1.6	20
15	Inverse Agonists: Tools to Reveal Ligand-Specific Conformations of G Protein-Coupled Receptors. <i>Science Signaling</i> , 2004, 2004, pe1-pe1.	1.6	19
16	The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. <i>British Journal of Pharmacology</i> , 2017, 174, 4523-4539.	2.7	19
17	Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3455-3463.	1.7	15
18	Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 195, 172949.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. <i>European Journal of Pharmacology</i> , 2014, 737, 140-148.	1.7	13
20	Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6381-6396.	2.9	12
21	Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. <i>PLoS ONE</i> , 2016, 11, e0167240.	1.1	10
22	Preface to DMR special edition "Cannabinoid receptors and ligands: therapeutic drug development and abuse potential". <i>Drug Metabolism Reviews</i> , 2018, 50, 1-2.	1.5	8
23	The tamoxifen derivative ridaifen-B is a high affinity selective CB 2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. <i>Toxicology and Applied Pharmacology</i> , 2018, 353, 31-42.	1.3	8
24	Non-Selective Cannabinoid Receptor Antagonists, Hinokiresinols Reduce Infiltration of Microglia/Macrophages into Ischemic Brain Lesions in Rat via Modulating 2-Arachidonolyglycerol-Induced Migration and Mitochondrial Activity. <i>PLoS ONE</i> , 2015, 10, e0141600.	1.1	7
25	Preclinical assessment of utility of M6S for multimodal acute and chronic pain treatment in diabetic neuropathy. <i>Life Sciences</i> , 2018, 192, 151-159.	2.0	6
26	Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with $\Delta^9$ -Tetrahydrocannabinol and JWH-018. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 259-269.	1.3	4
27	7-Azaindoquinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127501.	1.0	4
28	Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid <i>N</i> -(adamantan-1-yl)-1-(5-fluoropentyl)-1 <i>H</i> -indole-3-carboxamide (STS-135). <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00561.		
29	Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors. <i>Toxicological Sciences</i> , 2022, 187, 175-185.	1.4	4
30	Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1 <i>H</i> -indole-3-carboxylate (FDU-PB-22). <i>Xenobiotica</i> , 2019, 49, 1388-1395.	0.5	3
31	Pinprick hypo- and hyperalgesia in diabetic rats: Can diet content affect experimental outcome?. <i>Neuroscience Letters</i> , 2018, 673, 24-27.	1.0	2
32	Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. <i>Molecules</i> , 2020, 25, 4820.	1.7	2
33	Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development. <i>Life Sciences</i> , 2021, 285, 119993.	2.0	1
34	Human UDP-glucuronosyltransferases (UGTs) are involved in the metabolism of the natural resveratrol analogues arachidinol, arachidinol and piceatannol. <i>FASEB Journal</i> , 2010, 24, 967.12.	0.2	1
35	Tolerance and cross-tolerance among high-efficacy synthetic cannabinoids JWH-018 and JWH-073 and low-efficacy phytocannabinoid $\Delta^9$ -THC. <i>FASEB Journal</i> , 2013, 27, 1097.1.	0.2	1
36	Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3049.	1.8	1

#	ARTICLE	IF	CITATIONS
37	Major Metabolites of the Synthetic Cannabinoid 5F-AKB Retain High Affinity and Full Efficacy at CB1 Receptors; Potential Mechanism Contributing to Enhanced Toxicity?. FASEB Journal, 2021, 35, .	0.2	0
38	Gambogic acid binds to human CB2 receptors and exhibits potential partial agonist activity. FASEB Journal, 2010, 24, 769.1.	0.2	0
39	The omega and omega-1 monohydroxyl metabolites of the abused K2/Spice synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as agonists at human cannabinoid 2 receptors (hCB2s). FASEB Journal, 2012, 26, 660.8.	0.2	0
40	Functional consequences of synthetic cannabinoid metabolites and CYP2C9 polymorphisms (838.4). FASEB Journal, 2014, 28, 838.4.	0.2	0
41	In vitro and In vivo Effects of Phase 1 Hydroxylated Metabolites of the Synthetic Cannabinoid AB-PINACA [(S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide]. FASEB Journal, 2015, 29, 825.1.	0.2	0